Quarterly ResultAug 11, 2026, 05:28 PM
Eupraxia Q2 Net Loss $(14.49M); Advances EP-104GI Clinical Trials
AI Summary
Eupraxia Pharmaceuticals reported a net loss of $(14.49) million for Q2 2026, an increase from $(8.75) million in Q2 2025, though loss per share improved to $(0.23). The company highlighted positive new data for its EP-104GI candidate from the RESOLVE trial, demonstrating improvement in fibrosis and inflammation. Eupraxia also strengthened its leadership team and confirmed it is well-funded to advance its Phase 2b Eosinophilic Esophagitis (EoE) trial, with interim data anticipated in Q4 2026.
Key Highlights
- Q2 2026 net loss was $(14.49) million, up from $(8.75) million in Q2 2025.
- Loss per share for Q2 2026 improved to $(0.23) from $(0.26) in Q2 2025.
- Research and development expenses rose to $12.81 million in Q2 2026, from $5.20 million in Q2 2025.
- Cash and cash equivalents totaled $52.43 million as of June 30, 2026.
- Short-term investments reached $81.23 million as of June 30, 2026.
- Successfully raised $58.6 million (net) from a public offering in February 2026.
- Presented new data at DDW showing EP-104GI improved fibrosis and inflammation.
- Interim data from Phase 2b EoE trial for EP-104GI expected in Q4 2026.
Price Impact
More from EPRX
Clinical TrialOct 9, 8:36 AM
Eupraxia Pharmaceuticals to Present EoE Trial Data at ACG and UEG Conferences
Clinical TrialAug 13, 8:16 AM
Eupraxia Reports Positive Phase 1b/2a RESOLVE Trial Data for EP-104GI
Quarterly ResultAug 11, 5:24 PM
Eupraxia Reports Positive EP-104GI Clinical Data; Strengthens Team